Gilead Stock News

Gilead Sciences has outperformed the S&P 500 with a 19% total return since my last 'Buy' rating in August last year. Yet, the stock trades at a low PE ratio, especially after trading down over the pas

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from its virology research and development programs that will be presented at IDWeek 2023, October 1

Autologous chimeric antigen receptor T cell therapy is 0ne of the most promising, relatively new types of cancer treatments. CAR T involves “reprogramming” patients' T cells, which fight hostile c

AbbVie is entering a new era but is well prepared to return to its winning ways. Gilead Sciences offers investors steady and reliable performance and a great dividend.

Gilead's (GILD) Veklury gets a positive CHMP opinion, recommending the use of the drug to treat people with COVID-19 with mild to severe hepatic impairment.

Bank of America expects the Gilead Sciences to jump about 30%, as quoted on CNBC.

Gilead's (GILD) breast cancer drug Trodelvy, in combination with Keytruda, shows positive data in a phase II lung cancer study.

#Morningstar  #PfizerStock #DividendStocks Dividend investors: Put these cheap stocks on your buy list. 00:00 Introduction 00:28 Pfizer PFE 01:03 Medtronic MDT 01:34 Gilead Sciences GILD Susan Dziub

Wall Street underestimates the prospects of Pfizer and Gilead Sciences, given their significant role in developing vaccines and medicines against COVID-19. Gilead Sciences' revenue has remained stable

The "Halftime Report" traders debate the biggest analyst calls of the day.

BofA upgraded shares of biotech Gilead to Buy from Neutral, and lifted the target price to $95 from $88.

Gilead Sciences, Inc. (NASDAQ:GILD ) Wells Fargo Healthcare Conference September 6, 2023 11:00 AM ET Company Participants Andrew Dickinson - Chief Financial Officer Conference Call Participants Mohit

CNBC's Halftime traders Steve Weiss, Liz Young, Joe Terranova, and Brian Belski discuss the call of the day: health care.

Arcus Biosciences, Inc. stock has dropped 40% since its high in 2022, making it an attractive investment opportunity. The company has major deals with Gilead, Roche/Genentech, and AstraZeneca, and a l

Drugmakers are often great dividend payers, and AbbVie and Gilead are among the best. AbbVie sales are currently dropping, but that shouldn't last for too long.